Genelux (GNLX) Expected to Post Earnings on Thursday

Genelux (NASDAQ:GNLX) is projected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.20) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, analysts expect Genelux to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Genelux Stock Up 1.4%

NASDAQ GNLX opened at $2.98 on Tuesday. The company has a market cap of $133.62 million, a PE ratio of -3.51 and a beta of 0.58. Genelux has a 52 week low of $2.29 and a 52 week high of $8.53. The firm’s 50-day simple moving average is $2.95 and its two-hundred day simple moving average is $2.78.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GNLX. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Genelux from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Genelux currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Insider Transactions at Genelux

In other news, Director John Thomas sold 10,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $2.98, for a total transaction of $29,800.00. Following the sale, the director directly owned 472,784 shares in the company, valued at $1,408,896.32. This represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John W. Smither sold 12,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $2.91, for a total value of $34,920.00. Following the sale, the director owned 91,403 shares in the company, valued at approximately $265,982.73. This represents a 11.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 25,865 shares of company stock valued at $76,110 in the last ninety days. Insiders own 7.50% of the company’s stock.

Institutional Trading of Genelux

Institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in shares of Genelux during the 4th quarter valued at $222,000. Millennium Management LLC purchased a new stake in shares of Genelux in the fourth quarter worth $455,000. Balyasny Asset Management L.P. purchased a new stake in shares of Genelux in the fourth quarter worth $94,000. Align Financial LLC bought a new stake in Genelux during the fourth quarter valued at $123,000. Finally, 683 Capital Management LLC bought a new stake in Genelux during the fourth quarter valued at $572,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.